First AI-enabled continuous glucose monitor launched in Australia
"Managing glucose levels requires constant, complex decisions, often based on highly variable data," explains Associate Professor Neale Cohen, Director of Clinical Services at the Baker Heart and Diabetes Institute.
"Integrating AI to forecast low glucose risk is a meaningful step forward. This predictive capability offers better decision support that has the potential to significantly improve Time In Range (TIR) and ease anxiety around severe hypoglycaemia."
The Accu-Chek SmartGuide solution includes three integrated elements: the Accu-Chek SmartGuide CGM sensor, the Accu-Chek SmartGuide App, and the Accu-Chek SmartGuide Predict App.
The Accu-Chek SmartGuide CGM sensor provides 14 days of real-time glucose values.
The built-in, AI-trained algorithms include these key predictive features:
- Forecasting of glucose levels up to two hours ahead
- Estimation of the risk of nighttime hypoglycaemia
- Indication of hypoglycaemia risk within the next 30 minutes
The Accu-Chek SmartGuide® CGM solution is now available to Australian adults (18 years and older) via a private, out-of-pocket payment model through www.accu-chek.com.au
The manufacturer is advocating for subsidised access for people with type 1 diabetes and people with type 2 diabetes on multiple daily injections.
If you would like to discuss your diabetes management with a health professional, get in touch with the team at Diabetes Care Plus. Book today!